Global Market Bulletin
  • Home
  • Stock Market News
  • Investing
  • Economy
  • CEO Interviews
  • Contact Us
No Result
View All Result
SUBSCRIBE
Global Market Bulletin
  • Home
  • Stock Market News
  • Investing
  • Economy
  • CEO Interviews
  • Contact Us
No Result
View All Result
Global Market Bulletin
No Result
View All Result
Home Stock Market News

Eli Lilly & Co’s Q3 2024 Results: Revenue Up 42% After New Product Launches

by Global Market Bulletin
October 30, 2024
in Stock Market News
0
Eli Lilly & Co’s Q3 2024 Results: Revenue Up 42% After New Product Launches

Fetch Robotics Expands Market Reach Following Zebra Technologies Acquisition

1
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Eli Lilly and Company (LLY) has reported robust third-quarter financial results, showcasing substantial growth driven by demand for its recent product launches, particularly in diabetes and obesity treatments.

You might also like

AI + Cloud + Undervalued? Why Zenvia (ZENV) Could Be a 10X Play by 2026

Forget NVIDIA—Alarum Technologies (ALAR) is Quietly Building the Infrastructure for the Next Data Wave

CoreCard (CCRD)’s Surge is Just the Beginning of a Long-Term Fintech Rally

Eli Lilly and Company, founded in 1876 by Colonel Eli Lilly in Indianapolis, Indiana, is a global pharmaceutical leader known for its pioneering work in biotechnology, chemistry, and genetic medicine. With nearly 150 years of innovation, the company has developed groundbreaking treatments in diabetes, cancer, immunology, and neuroscience, benefiting millions worldwide.

Lilly has been at the forefront of diabetes care with drugs like Humalog and Trulicity, while also advancing Alzheimer’s treatments and therapies for autoimmune diseases. Headquartered in Indianapolis, Lilly continues to invest heavily in R&D, with a focus on addressing significant global health challenges and making treatments more accessible.

Eli Lilly’s Q3 2024 Results: Revenue Up 42% After New Product Launches

CHECK THIS OUT: PayPal Beats Q3 Forecasts, Lifts Full-Year Outlook on Strong Growth

Mounjaro and Zepbound Boost Eli Lilly’s Q3 2024 Revenue to Record $11.4 Billion

Eli Lilly’s total revenue for Q3 reached $11.44 billion, marking a 20% increase from the previous year. Excluding divestitures, revenue surged by 42%, underscoring the solid performance of Lilly’s innovative treatments, including Mounjaro and Zepbound.

CEO David A. Ricks praised the quarterly results, emphasizing the continued demand for Lilly’s new therapies and the expanding impact of its portfolio.

“Lilly’s trajectory is driven by significant growth in both our incretin and non-incretin revenue streams,” Ricks noted, adding that the company’s pipeline advancements signal even greater growth prospects.

Key contributors to the quarter’s performance included:

  • Revenue from New Products: Revenue from products launched since 2022, including Mounjaro and Zepbound, grew by $3.07 billion to $4.51 billion in Q3, while growth products introduced before 2022 also saw gains.
  • U.S. Market Strength: Domestic revenue jumped 46% to $7.81 billion, propelled by a 35% volume increase and higher realized prices.
  • Global Expansion: Excluding divested assets, international revenue rose 33%, largely fueled by strong sales of Mounjaro and Verzenio.

Eli Lilly’s Q3 2024 EPS Hits $1.07 as New Product Approvals Drive Revenue Growth

Lilly also posted earnings per share (EPS) of $1.07 on a reported basis, reflecting a net income turnaround from last year’s Q3 loss. Adjusted non-GAAP EPS stood at $1.18, driven by the volume and favorable pricing.

However, significant investment in research and development (up 13% to $2.73 billion) reflected Lilly’s commitment to its expanding pipeline, including new product approvals like Ebglyss for atopic dermatitis and Kisunla for Alzheimer’s.

In addition, Lilly raised its full-year revenue guidance to $45.4 to $46.0 billion, expecting to benefit from recent FDA and Japanese approvals, key R&D advances, and strengthened manufacturing infrastructure. The company’s adjusted EPS guidance was updated to between $13.02 and $13.52 to reflect ongoing investments.

As Eli Lilly continues its focus on bringing new treatments to market, its financial growth showcases strong market positioning, with further innovation in immunology, diabetes, and Alzheimer’s potentially enhancing its competitive edge.

READ ALSO: JetBlue Exceeds Q3 Targets, Boosts Premium Offerings with EvenMore® and Elon Musk’s Net Worth Jumps $30 Billion as Tesla Shares Surge 22%.

Tags: Eli Lilly and Company (LLY)
ShareTweet
Global Market Bulletin

Global Market Bulletin

Global Market Bulletin is a leading provider of stock market updates, economic news, and personalized investing guides. Our team brings you the latest global financial information to help you make smart investment decisions. About the Editorial Team Our editorial team consists of financial experts and seasoned market analysts who bring decades of experience to our coverage. With a commitment to unbiased reporting, our team ensures that every article is backed by thorough research and delivers accurate financial insights.

Recommended For You

AI + Cloud + Undervalued? Why Zenvia (ZENV) Could Be a 10X Play by 2026

by Global Market Bulletin
June 14, 2025
0
AI + Cloud + Undervalued? Why Zenvia (ZENV) Could Be a 10X Play by 2026

Zenvia Inc. (NASDAQ:ZENV) is a Brazilian-born cloud communications platform empowering businesses across Latin America with flexible, omnichannel engagement tools. Headquartered in São Paulo and listed on the NASDAQ,...

Read moreDetails

Forget NVIDIA—Alarum Technologies (ALAR) is Quietly Building the Infrastructure for the Next Data Wave

by Global Market Bulletin
June 14, 2025
0
Forget NVIDIA—Alarum Technologies (ALAR) is Quietly Building the Infrastructure for the Next Data Wave

Alarum Technologies Ltd. (NASDAQ:ALAR) is a next-generation cybersecurity and web intelligence company headquartered in Herzliya, Israel, with a growing international presence. Formerly known as Safe-T Group Ltd., the...

Read moreDetails

CoreCard (CCRD)’s Surge is Just the Beginning of a Long-Term Fintech Rally

by Global Market Bulletin
June 14, 2025
0
CoreCard (CCRD)’s Surge is Just the Beginning of a Long-Term Fintech Rally

CoreCard Corporation (NYSE:CCRD) is a fast-rising force in the financial technology sector, specializing in comprehensive card management and transaction processing solutions for banks, financial institutions, and fintech companies....

Read moreDetails

Is PLAYSTUDIOS (MYPS) the Next Gaming Giant? Here’s Why Bulls Are Betting Big

by Global Market Bulletin
June 14, 2025
0
Is PLAYSTUDIOS (MYPS) the Next Gaming Giant? Here’s Why Bulls Are Betting Big

PLAYSTUDIOS Inc. (NASDAQ:MYPS) is a trailblazing developer and publisher of free-to-play mobile and social games that uniquely blend entertainment with real-world value through its patented rewards platform, playAWARDS....

Read moreDetails

NetClass Technology (NTCL): Could This Be the Next Duolingo—With More AI?

by Global Market Bulletin
June 13, 2025
0
NetClass Technology (NTCL): Could This Be the Next Duolingo—With More AI?

NetClass Technology Inc. (NASDAQ:NTCL) is a fast-emerging education technology company based in Shanghai, China, dedicated to revolutionizing the learning experience through artificial intelligence and smart digital infrastructure. Founded...

Read moreDetails

Browse by Category

  • CEO Interviews
  • Economy
  • Investing
  • Stock Market News
  • Uncategorized

QUICK LINKS

  • Stock Market News
  • Investing
  • Economy
  • Contact Us
  • About Global Market Bulletin
  • Editorial Policy – Global Market Bulletin
  • Our Editorial Team

RECENT POSTS

  • AI + Cloud + Undervalued? Why Zenvia (ZENV) Could Be a 10X Play by 2026
  • Forget NVIDIA—Alarum Technologies (ALAR) is Quietly Building the Infrastructure for the Next Data Wave
  • CoreCard (CCRD)’s Surge is Just the Beginning of a Long-Term Fintech Rally

GET EMAIL MARKET UPDATES

Subscribe to our mailing list to receives daily updates direct to your inbox!
  • Privacy Policy
  • Terms and Conditions

© 2022 Global Market Bulletin. All Rights Reserved.

No Result
View All Result
  • Home
  • Stock Market News
  • Investing
  • Economy

© 2022 Global Market Bulletin. All Rights Reserved.

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?